ALL, Childhood
14
5
6
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
14.3%
2 terminated out of 14 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Childhood Cancer Survivors' Affective Response to Exercise
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
Retun-to-school Adaptation Program for Children With Cancer
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors